ReviewSeminars in immunopathology2025
Microbiota-dependent modulation of intestinal anti-inflammatory CD4
Review in Seminars in immunopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The gut microbiota-miRNA axis in multiple sclerosis: Mechanisms and therapeutic potentials.Folia microbiologica · 2026Review
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
- FUT2-mediated α1,2-fucosylation in inflammatory bowel disease: mechanisms and translational potential.Molecular biology reports · 2026Review
- Review
- Stem cell-based tactics in the remodeling and treatment of intestinal diseases.Stem cell research & therapy · 2026Review
- The Role of CD4Cells · 2026Review
- Decoding the microbial-local immune dialogue in liver cancer: from ecological drivers to precision therapeutics.Frontiers in oncology · 2025Review
- Communication between gut microbiota-derived metabolites and the tumor microenvironment.Frontiers in immunology · 2025Review
- Targeting the role played by microbiota and adaptive immunity within autoimmune disease complexity.Frontiers in immunology · 2025Article
- Gan-du-qing attenuates PMFrontiers in medicine · 2025Article
- Mechanisms and therapeutic strategies of macrophages and neutrophils inducing ulcerative colitis progression.Frontiers in immunology · 2025Review
- Fundamental and emerging insights into innate and adaptive immunity in inflammatory bowel diseases.Frontiers in immunology · 2025Review
- The gut microbiome in lung cancer: from pathogenesis to precision therapy.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Barrier organs such as the gastrointestinal tract, lungs, and skin are colonized by diverse microbial strains, including bacteria, viruses, and fungi. These microorganisms, collectively known as the commensal microbiota, play critical roles in maintaining health by defending against pathogens, metabolizing nutrients, and providing essential metabolites. In the gut, commensal-derived antigens are frequently sensed by the intestinal immune system. Maintaining tolerance toward these beneficial microbial species is crucial, as failure to do so can lead to chronic inflammatory conditions like inflammatory bowel disease (IBD) and can even affect systemic immune or metabolic health. The immune system carefully regulates responses to commensals through various mechanisms, including the induction of anti-inflammatory CD4⁺ T cell responses. Foxp3⁺ regulatory T cells (Foxp3
Indexed as
Identifiers
40167791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.